Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, C. Q.
Right arrow Articles by Tsao, M.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, C. Q.
Right arrow Articles by Tsao, M.-S.
Clinical Cancer Research Vol. 10, 1984-1991, March 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker

Chang Qi Zhu1, Fiona H. Blackhall2,6, Melania Pintilie2, Pratibha Iyengar3, Ni Liu1, James Ho1, Taylor Chomiak1, Davina Lau1, Timothy Winton2,5, Frances A. Shepherd2,6 and Ming-Sound Tsao1,2,3,4

1 University Health Network, Ontario Cancer Institute and 2 Princess Margaret Hospital, and 3 Departments of Laboratory Medicine and Pathobiology, 4 Medical Biophysics, 5 Surgery, and 6 Medicine, University of Toronto, Toronto, Ontario, Canada

Purpose: Skp2 plays a critical role in cell cycle progression, especially at the G1-S transition, putatively through its control of several cell cycle regulator proteins. The Skp2 gene is located on a region of chromosome 5p that is commonly overrepresented in lung cancer. The present study aimed to evaluate Skp2 abnormalities and their prognostic value in non-small cell lung cancer (NSCLC).

Experimental Design: In total 16 NSCLC cell lines and 163 primary tumors were included in studies to measure Skp2 relative gene copy number, mRNA abundance, and protein level. The tumors were also evaluated for p27 protein expression level and ras mutation. These values were correlated with the clinical and pathological features of the patients.

Results: Skp2 relative gene copy number aberrations were found in 88 and 65% of NSCLC cell lines and primary tumors, respectively. Overrepresentation was especially common among squamous cell carcinoma (74%). Both gene copy overrepresentation (13%) and loss (35%) were found in adenocarcinoma. Skp2 relative gene copy number was significantly correlated with mRNA and protein levels, but none of these were correlated with p27 protein levels. Neither high Skp2 protein expression nor ras mutation was prognostically significant. In NSCLCs with ras mutation, however, high Skp2 protein expression was a significant independent poor prognostic marker.

Conclusion: There appears to be a synergistic interaction between high Skp2 protein expression and ras mutation with negative impact on the survival of NSCLC patients.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
C.-Q. Zhu, S. N. Popova, E. R. S. Brown, D. Barsyte-Lovejoy, R. Navab, W. Shih, M. Li, M. Lu, I. Jurisica, L. Z. Penn, et al.
Integrin {alpha}11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells
PNAS, July 10, 2007; 104(28): 11754 - 11759.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. K. Cheng, L. W.C. Chow, W. T.Y. Loo, T. K. Chan, and V. Chan
The Cell Cycle Checkpoint Gene Rad9 Is a Novel Oncogene Activated by 11q13 Amplification and DNA Methylation in Breast Cancer
Cancer Res., October 1, 2005; 65(19): 8646 - 8654.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Mani and E. P. Gelmann
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
J. Clin. Oncol., July 20, 2005; 23(21): 4776 - 4789.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Qian, J. Niu, M. Li, P. J. Chiao, and M.-S. Tsao
In vitro Modeling of Human Pancreatic Duct Epithelial Cell Transformation Defines Gene Expression Changes Induced by K-ras Oncogenic Activation in Pancreatic Carcinogenesis
Cancer Res., June 15, 2005; 65(12): 5045 - 5053.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.